CEPI—a new global R&D organisation for epidemic preparedness and response

The Lancet

Volumn 389, Issue 10066, 2017, Pages 233-235

  Brende, Børge ^a   Farrar, Jeremy ^b   Gashumba, Diane ^c   Moedas, Carlos ^d   Mundel, Trevor ^e   Shiozaki, Yasuhisa ^f   Vardhan, Harsh ^g   Wanka, Johanna ^h   Røttingen, John Arne ^i,j,k  

^a Norwegian Ministry of Foreign Affairs   (Norway)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c Ministry of Health   (Rwanda)

^d EUROPEAN COMMISSION   (Belgium)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f Japan Ministry of Health Labour and Welfare   (Japan)

^g DEPARTMENT OF BIOTECHNOLOGY   (India)

^h Federal Ministry of Education and Research   (Germany)

ⁱ NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^j UNIVERSITY OF OSLO   (Norway)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

DISASTER PLANNING; DRUG RESEARCH; EPIDEMIC; FUNDING; HEALTH PROGRAM; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; NON PROFIT ORGANIZATION; NOTE; PRIORITY JOURNAL; HUMAN; PUBLIC HEALTH SERVICE;

EPIDEMICS; HUMANS; INTERNATIONAL COOPERATION; PUBLIC HEALTH PRACTICE;

EID: 85009752508     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30131-9     Document Type: Note

References (8)

1. 1 Gostin, LO, Tomori, O, Wibulpolprasert, S, et al. Toward a common secure future: four global commissions in the wake of Ebola. PLoS Med, 13, 2016, e1002042.
2. 2 Kieny, MP, Røttingen, JA, Farrar, J, on behalf of the WHO R&D Blueprint team the R&D Blueprint Scientific Advisory Group. The need for global R&D coordination for infectious diseases with epidemic potential. Lancet 388 (2016), 460–461.
3. 3 Matthiessen, L, Colli, W, Delfraissy, JF, Hwang, ES, Mphahlele, J, Ouellette, M, on behalf of GloPID-R members. Coordinating funding in public health emergencies. Lancet 387 (2016), 2197–2198.
4. 4 Henao-Restrepo, AM, Longini, IM, Egger, M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
5. 5 Henao-Restrepo, AM, Camacho, A, Longini, IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet, 2016 published online first Dec 22. http://dx.doi.org/10.1016/S0140-6736(16)32621-6.
6. 6 Heymann, DL, Hodgson, A, Sall, AA, et al. Zika virus and microcephaly: why is this situation a PHEIC?. Lancet 387 (2016), 719–721.
7. 7 Vannice, KS, Giersing, BK, Kaslow, DC, et al. Meeting report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine, 2016, 10.1016/j.vaccine.2016.10.034 published online Dec 1.
8. 8 Røttingen J-A, Gouglas D, Feinberg M, et al. New vaccines against epidemic infectious diseases. New Engl J Med (in press).